In the commercial world, there is the Pepsi taste test to see if blinded individuals prefer Pepsi over Coke. Although not a perfect analogy, in the scientific world, insulin-like growth factor I (IGF-I) exists in multiple "flavors" of peptide sequences, and the question addressed by Barton's exciting paper (2) in this issue is which IGF-I flavor is better for skeletal muscle?
IGF-I, in its many forms, plays a critical role in development, growth, repair, and maintenance of skeletal muscle. IGF-I stimulates differentiation of cultured L6 myoblasts (6) ; immunohistochemical levels of IGF-I increase within satellite cells of regenerating muscle (10); IGF-I stimulates proliferation to a small degree and has a more pronounced stimulation of differentiation in primary cultured satellite cells (1); mechanical-overloaded muscle has an eightfold rise in IGF-I mRNA in rats devoid of growth hormone, providing evidence of an autocrine or paracrine role for IGF-I in skeletal muscle hypertrophy (5); and transgenic mice overexpressing a dominant negative IGF-I receptor specifically in skeletal muscle exhibit reduced muscle mass and hypoplasia from birth to 3 wk of age but then develop hyperplasia and continue to have a reduced muscle mass as they grow to adulthood (7) .
In 1985, IGF-I was shown by Bell et al. (3) to contain two 3Ј sequences (Ea and Eb) in mouse liver mRNA that resulted from alternative splicing of a 52-base pair sequence in the E domain, which changes the reading frame resulting in different IGF-IEa and IGF-IEb peptides. In 1996, Geoffrey Goldspink (8) found that skeletal muscle subjected to stretch-induced hypertrophy upregulated IGF-IIEb mRNA in skeletal muscle and named it "mechano-growth factor" (MGF) because a mechanical stimulus had caused its increase. After extensive additional studies, summarized by Goldspink (8) , he suggested that MGF is more effective in producing muscle hypertrophy than IGF-IEa because MGF is responsible for the initial activation of satellite (stem) cells, and thus he contends that MGF "'kick starts' the hypertrophy/repair process." However, controversy remains, mainly due to the lack of alternative approaches to compare various IGF-I isoforms. Using the genetransfer technique of adeno-associated virus (AAV), Barton (2) directly tests the efficacy of IGF-IEa vs. MGF (termed IGF-IA and IGF-IB, respectively, in her paper; Table 1 ) in producing skeletal muscle hypertrophy. For simplicity of reading this commentary, terminology used by Barton (2) is employed (Table 1) . Surprisingly Barton's results do not conform to Goldspink's suggestion (8) that IGF-IB is more efficient in the production of hypertrophy. When AAV are injected into the extensor digitorum longus muscle of 2-to 3-wk-old mice, no differences in the amount of hypertrophy (12 and 7% for IGF-IA and IGF-IB, respectively) were observed for the time points of 2 and 4 mo postinjection. An additional surprise was that although the percentages of hypertrophy were not statistically different, the AAV expressing IGF-IB raised the total IGF-I levels manyfold greater than IGF-IA. Barton speculates that there is a threshold of tissue IGF-I above which there is no additional hypertrophy, so additional studies are needed.
Four months after AAV injections into the extensor digitorum longus muscle of 6-mo-old mice, only muscles with IGF-IA expressed from the injected AAV had hypertrophy (a 5% larger muscle). Thus, under the conditions (AAV gene transfer) used by Barton (2), neither the 2-to 3-wk-nor the 6-mo-old mice support the suggestion of Goldspink (8) that IGF-IB is more effective than IGF-IA in producing hypertrophy.
Rosenthal (12) has called for an elucidation of the signaling mechanisms of the different IGF-I isoforms. Barton (2) has answered, in part, this request. Four weeks after 2-to 3-wk-old mice had AAV injections, the relative phosphorylations of the IGF-I receptor, Akt, and ERK1/2 were greater for IGF-IB than IGF-IA (2). Indeed, IGF-IA did not increase the phosphorylation of ERK1/2. Barton's observation (2) that IGF-IB increases ERK1/2 phosphorylation supports the contention that IGF-B expression in C2C12 myoblasts could activate proliferation while IGF-IA preferentially enhances differentiation (8) . IGF-I has been shown to activate myoblasts thorough ERK1/2 signaling (11) and, subsequently, to induce differentiation through phosphoinositol 3-kinase/Akt signaling (12). These results are further supported by time course data from other investigators. In response to bupivacaine-induced regeneration (8) or resistance exercise (9), the increase and peak of IGF-IB mRNA in skeletal muscle precedes IGF-IA mRNA's increase (consistent with IGF-IB's role in proliferation as muscle cell proliferation proceeds differentiation). Thus Barton's results (2) are important extensions of some of the notions presented by Goldspink (8) .
The trend for hypertrophy to lessen from 2 to 4 mo postinjection with AAV expressing either IGF-IA or IGF-IB is reminiscent of an earlier report of an attenuation of gastrocnemius muscle hypertrophy in transgenic mice overexpressing IGF-I in skeletal muscle as they age from 1 to 18 mo of age (4) . Interestingly, Akt phosphorylation in satellite cells was inverted from 1 mo of age (where transgenic IGF-I mice Ͼ wild-type mice) to 18 mo of age (transgenic IGF-I mice Ͻ wild-type mice) (4) . A future research direction will need to compare the short-term vs. long-term benefits of IGF on skeletal muscle mass and to compare signaling cascades under such circumstances. Such information seems crucial to realize the therapeutic potential of IGF-I to increase muscle mass. Additional studies are also needed to determine why preferential engagement of ERK1/2 signaling by IGF-IB is associated with less hypertrophy, and whether this difference is due to IGF-IB's better activation of satellite cell proliferation? Finally, it will be of great interest to determine which IGF-I isoform is the best flavor for reinvigorating muscle health.
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